SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Munch-a-Biotech Today
An SI Board Since December 1998
Posts SubjectMarks Bans
3158 136 0
Emcee:  Biomaven Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2558$720M for what's effectively a preclinical company seems like a lot of moneyrkrw-4/22/2008
2557Rick, I guess you mean that you agree with Birchenough's comments: <WithBiotech Jim-4/22/2008
2556Yep I think the same too. If any of the SIRT drugs work, awesome...If not lost sdr.praveen-4/22/2008
2555Rick- I was wondering if anyone was going to respond to my speculations... Biotech Jim-4/22/2008
2554Another opinion needed here: I think it shows gsk is desperate!keokalani'nui-4/22/2008
2553Cool but i still think the price they were offered is very cheap.dr.praveen-4/22/2008
2552:-) that's one explanation. another is that it doesn't work for my parscaram(o)uche-4/22/2008
2551..that's why you are sitting and watching, because resveratrol supplement isejgopher-4/22/2008
2550SIRT really distinguished itself in the polish of its investor presentations, anDewDiligence_on_SI-4/22/2008
2549Mine too!!!!!!!!!!!!!!!..signed up for their email alerts and that's as far zeta1961-4/22/2008
2548It’s a dirty job but someone’s gotta do it!DewDiligence_on_SI-4/22/2008
2547Cash that would have been spent. Lucky guy is the incy ceo, was named to the brkrw-4/22/2008
2546The effective price is about $620M net of SIRT’s cash.DewDiligence_on_SI-4/22/2008
2545and I take a resveratrol supplement every day. just sitting and watching, la tescaram(o)uche-4/22/2008
2544Sh*t (https://www.siliconinvestor.com/nfvda/boards/read_msg.asp?message_id=28704DewDiligence_on_SI-4/22/2008
2543My sentiments exactly!!!rkrw-4/22/2008
2542>> USD720 million << arrrrrrrrrrrrrrrrgggggggggggggggggghhhhhhhhhhhscaram(o)uche-4/22/2008
2541Sirtris munched. Too bad. 2M shares short! Press Release Source: GlaxoSmithKrkrw-4/22/2008
2540>> MYGN for flurbie, no way << The phase II trial failed, as we knoscaram(o)uche-4/22/2008
2539>> I cannot seem to fathom a RIGL bid due to the tox seen clinically. <scaram(o)uche-4/22/2008
2538GTXI is a mrk possibility, more so as time goes by. Obviously damages the P&keokalani'nui-4/22/2008
2537SRDX would be a problematic acquisition for MRK (or any drug company), IMO. SRDewDiligence_on_SI-4/22/2008
2536<i>What do you think Merck's definition of midcap is?</i> Goodpgo-neil-4/22/2008
2535My guesses would be POZN (lol, just kidding). INCY for the JAK program to get Biotech Jim-4/21/2008
2534<<Schizophrenia maybe NPSP's mGluR programs are of interest? But that NeuroInvestment-4/21/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News